BGM Group Ltd. (BGM): Total Liabilities
$41.92M
As of 2025-09-30
+63.7%
3-year compound annual growth
+16.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $41.92M | +370.4% | 2026-07-21, Balance as of period end |
| 2024-09-30 | $8.91M | +29.0% | 2026-07-21, Balance as of period end |
| 2023-09-30 | $6.91M | -27.8% | 2025-04-03, Balance as of period end |
| 2022-09-30 | $9.56M | -48.8% | 2024-02-15, Balance as of period end |
| 2021-09-30 | $18.68M | -3.2% | 2023-04-19, Balance as of period end |
| 2020-09-30 | $19.30M | +52.8% | 2022-10-13, Balance as of period end |
| 2019-09-30 | $12.63M | n/a | 2021-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $6.64M | -34.4% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $7.04M | -0.3% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $1.93M | -40.0% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $22.39M | -65.0% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
Compare BGM, LIFD, SBFM, ETST side by side · Screen every company in Pharmaceutical Preparations ↗